United States


GTXI.OQ on NASDAQ Stock Exchange Capital Market

23 Feb 2017
Change (% chg)

$-0.09 (-1.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for GTXI.OQ


GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its... (more)


Beta: 1.88
Market Cap(Mil.): $78.64
Shares Outstanding(Mil.): 15.92
Dividend: --
Yield (%): --


  GTXI.OQ Industry Sector
P/E (TTM): -- 44.59 29.71
EPS (TTM): -1.00 -- --
ROI: -168.81 -3.18 12.94
ROE: -168.81 5.86 14.09

BRIEF-Gtx's Enobosarm has been well tolerated among patients

* Enobosarm meets pre-specified primary efficacy endpoint in ongoing phase 2 clinical trial in ER+/AR+ breast cancer

Nov 28 2016

BRIEF-GTx achieves second stage 1 milestone in Phase 2 clinical trial

* Top line data from stage 1 of 9 mg cohort expected in December 2016

Nov 16 2016

BRIEF-GTX reports qtrly loss per share $0.05

* Gtx provides corporate update and reports third quarter 2016 financial results Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-GTX Inc says size of board increased to seven directors from six - SEC filing

* GTX Inc says board of directors increased size of board from six to seven directors - SEC filing Source: (http://bit.ly/2bUUwnO ) Further company coverage:

Sep 01 2016

BRIEF-GTx appoints Garry Neil to the board

* GTx appoints Dr. Garry Neil to board of directors Source text for Eikon: Further company coverage:

Sep 01 2016

More From Around the Web

Earnings vs. Estimates